NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Gonorrhea Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 921972
出版日期 內容資訊 英文 110 Pages
商品交期: 2-3個工作天內
全球淋病治療市場:成長,趨勢,及預測 Gonorrhea Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 110 Pages



第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 淋病負擔增加
    • 政府及民間部門在全國宣傳活動的參加度擴大
  • 市場阻礙因素
    • 嚴格的法規方案
    • 與性病門診患者相關的社會污名
  • 波特的五力分析

第5章 市場區隔

  • 各淋菌感染
    • 單純性淋球菌感染
    • 淋菌性關節炎
    • 淋菌性腦膜炎及心內膜炎
  • 不同治療
    • 單一療法
    • 雙重療法
  • 各終端用戶
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Allergan, Inc.
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Lupin Pharmaceuticals
    • Pfizer Inc.
    • Teligent, Inc.

第7章 市場機會及今後趨勢


Product Code: 67485

Gonorrhea is an infection caused by a sexually transmitted bacterium that infects both males and females. The primary factors such as the rising prevalence of gonorrhea, implementation of national screening programs and growing public awareness are propelling the growth of the gonorrhea therapeutics market. According to the Centers for Disease Control and Prevention (CDC), around 700,000 new cases of gonorrhea are detected each year. In 2019, the National Institute of Allergy and Infectious Diseases (NIAID) has granted USD 41.6 million over five years to support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea, and chlamydia. Thus, with the growing prevalence of STDs increases patient awareness through national campaigns and growing government initiatives are anticipated to drive market growth.

However, stringent regulatory scenarios and social stigma associated with patients visiting STD clinics are expected to restrain the growth of the global market in the forecast period.

Key Market Trends

Dual Therapy Segment is Expected to Register Good Growth Over the Forecast Period

By Treatment, the market has been segmented into monotherapy and dual therapy. Gonorrhea, caused by Neisseria gonorrhoeae, is the second most common bacterial STI and results in substantial morbidity. The dual therapy segment is estimated to dominate the global market, and this trend is expected to continue over the forecast period. Dual therapy with ceftriaxone and azithromycin is recommended as the first-line regimen for the treatment of gonorrhea. WHO recommends dual therapy over monotherapy for people with symptomatic and asymptomatic gonorrhea. Also, monotherapy is no longer a viable option in many settings worldwide. In addition, growing public awareness and a large patient pool also contribute to the growth of the gonorrhea therapeutics market.

North America is Estimated to Lead the Gonorrhea Therapeutics Market

North America is expected to lead the market, owing to high standards of healthcare infrastructure and easy availability of sophisticated technology in this region. As per CDC estimates, in 2018 around 583,405 cases of gonorrhea were reported in the United States. However, Europe and the Asia Pacific are followed next after North America owing to the increasing incidence of gonococcal infection, and the rise in collaboration of domestic and international companies in these regions. For instance, In 2019, Binx health announced that its proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval, which is expected to drive the gonorrhea therapeutics market in the forecast period.

Competitive Landscape

The market for gonorrhea therapeutics is consolidated in terms of competition with a presence of few major pharmaceutical companies. Some of the major players in the gonorrhea therapeutics market includes Allergan, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Lupin Pharmaceuticals, Pfizer Inc, Teligent, Inc., among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Gonorrhea
    • 4.2.2 Growing Government and Private Sector Participation Through National Campaigns
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Scenario
    • 4.3.2 Social Stigma Associated With Patients Visiting STD Clinics
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Gonococcal Infection
    • 5.1.1 Uncomplicated Gonococcal Infection
    • 5.1.2 Gonococcal Arthritis
    • 5.1.3 Gonococcal Meningitis and Endocarditis
  • 5.2 By Treatment
    • 5.2.1 Monotherapy
    • 5.2.2 Dual Therapy
  • 5.3 By End User
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Pharmacies
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle-East & Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Allergan, Inc.
    • 6.1.2 F. Hoffmann-La Roche Ltd
    • 6.1.3 GlaxoSmithKline plc
    • 6.1.4 Lupin Pharmaceuticals
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Teligent, Inc.